

EXPANDING ACCESS TO HIV TREATMENT

Gilead Sciences has played a central role in expanding access to HIV treatment in the developing world, with 2016 marking the 10-year anniversary of the company's innovative generic licensing agreements. With its partners, Gilead aims to reach 10 million people in developing countries with Gilead-based regimens by the end of 2016.

10 YEARS

10 MILLION PEOPLE

10 million people
on Gilead HIV medicines
(2016 target)

2.4 million people
on Gilead HIV medicines

30,000 people
on Gilead HIV medicines

2006

2011

2016

A DECADE OF PROGRESS

- To further expand access to treatment, Gilead **licenses its HIV medicines to multiple generic manufacturers**
- Competition among manufacturers begins to **drive down generic treatment costs**
- Gilead becomes the first innovator company to join the **Medicines Patent Pool**
- Gilead HIV drugs are registered in **105 developing countries**
- Gilead begins **adding pipeline medicines** to its generic licensing agreements
- Gilead HIV drugs are registered in over **110 developing countries**
- More than **20 generic manufacturers** in India, South Africa and China are licensed to produce Gilead HIV medicines
- Cost of generic versions of Gilead medicines have fallen by **more than 80%** since 2006



Gilead also supports the HIV response in the developing world by advancing the **SCIENCE** of treatment and building **PARTNERSHIPS** to extend the reach of prevention, screening and care.



SCIENCE

New treatments: Gilead's new generation of single tablet regimens may help reduce the cost of HIV therapy in developing countries even further.

Cure research: Gilead scientists are evaluating agents that expose dormant HIV-infected cells to the body's immune system and may one day lead to a cure.

Prevention: Pre-exposure prophylaxis (PrEP) is being widely adopted as an important HIV prevention tool.

Implementation science: Gilead also invests in on-the-ground studies, including PrEP demonstration projects and test-and-treat pilot programs, to provide new insights that can guide prevention and treatment policy. For example, in northern Tanzania, Gilead is partnering with the Vatican to screen 250,000 people for HIV at local health centers and provide treatment to 20,000 who are diagnosed.



PARTNERSHIPS

Gilead works with governments, NGOs, scientists, advocates, international funders and public health leaders to strengthen the response to HIV/AIDS in developing countries.

Medical education: In collaboration with Ministries of Health and regional business partners, Gilead provides HIV training for nurses, doctors and community health workers.

Infrastructure: With these partners, Gilead works to improve ARV supply chain management and register its HIV medicines—critical steps in expanding access to treatment.

Grantmaking: In 2014, Gilead was ranked the top corporate funder of HIV/AIDS programs worldwide by Funders Concerned About AIDS. The company's corporate contribution program provides vital support to non-profit partners that serve people living with or at risk for HIV. For example, Gilead supports DREAMS, a partnership including PEPFAR, the Bill & Melinda Gates Foundation and others to reduce HIV infections among adolescent girls and young women in sub-Saharan Africa.

Through these efforts, Gilead supports the **UNAIDS 90-90-90 target:**

- 90% of people living with HIV knowing their status •
- 90% of those diagnosed on treatment •
- 90% of those treated achieving viral suppression by 2020 •

To learn more about Gilead's developing world access programs, visit <http://www.gilead.com/responsibility>